Royal London Asset Management Ltd. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Royal London Asset Management Ltd. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 282,345 shares of the biopharmaceutical company's stock after selling 44,524 shares during the period. Royal London Asset Management Ltd. owned 0.22% of Alnylam Pharmaceuticals worth $68,610,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company's stock valued at $1,792,542,000 after buying an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock valued at $550,837,000 after acquiring an additional 201,784 shares during the period. Capital International Investors boosted its stake in Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company's stock worth $545,674,000 after acquiring an additional 64,560 shares in the last quarter. Capital Research Global Investors grew its holdings in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock worth $470,018,000 after purchasing an additional 214,908 shares during the period. Finally, Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $390,438,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares of the company's stock, valued at $30,013.84. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of the company's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares of the company's stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $3.05 during trading on Tuesday, reaching $256.21. 599,024 shares of the company traded hands, compared to its average volume of 901,072. The company has a market cap of $32.89 billion, a P/E ratio of -94.46 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $287.55. The firm has a fifty day simple moving average of $257.55 and a 200 day simple moving average of $192.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts' expectations of $447.22 million. The business's revenue was up 107.0% on a year-over-year basis. During the same period in the previous year, the business posted ($2.21) earnings per share. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the topic of a number of research analyst reports. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an "equal weight" rating in a report on Friday, July 12th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday. Finally, BMO Capital Markets reissued an "outperform" rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.